Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 184.2% in the third quarter, Holdings Channel.com reports. The firm owned 5,541 shares of the company’s stock after acquiring an additional 3,591 shares during the quarter. BNP Paribas Financial Markets’ holdings in Lexeo Therapeutics were worth $50,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Values First Advisors Inc. purchased a new stake in shares of Lexeo Therapeutics during the 3rd quarter worth $67,000. Rhumbline Advisers lifted its stake in shares of Lexeo Therapeutics by 37.3% in the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after purchasing an additional 3,627 shares during the period. Bank of New York Mellon Corp boosted its holdings in Lexeo Therapeutics by 12.3% during the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after buying an additional 3,483 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Lexeo Therapeutics by 107.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock worth $577,000 after buying an additional 33,013 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on LXEO. HC Wainwright upped their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Leerink Partners lowered their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th. Finally, Chardan Capital raised their price target on Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Lexeo Therapeutics currently has an average rating of “Buy” and a consensus target price of $23.80.

Lexeo Therapeutics Price Performance

LXEO stock opened at $6.04 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The stock’s 50 day moving average price is $7.95 and its 200 day moving average price is $11.05. The firm has a market cap of $199.72 million and a P/E ratio of -1.91. Lexeo Therapeutics, Inc. has a 1 year low of $5.77 and a 1 year high of $22.33.

Insider Transactions at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $8.10, for a total transaction of $40,500.00. Following the completion of the sale, the chief executive officer now directly owns 120,695 shares in the company, valued at $977,629.50. The trade was a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 10,000 shares of company stock valued at $80,550 over the last three months. 4.50% of the stock is currently owned by insiders.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.